Revolutionizing Uterine Care: Horizon’s The Moncton Hospital Leads Atlantic Canada with State-of-the-Art Technology May 14, 2024 Gynecologist Dr. Bruce Lee, the inventor of the Acessa® Fibroid Procedure and leading expert in the treatment of fibroids with radio frequency ablation (left) and gynecologist Dr. David Kogon (right) watch gynecologist Dr. Stephane Foulem perform the first procedure with the new device. (MONCTON) – Horizon’s The Moncton Hospital (TMH) is the sole facility in Atlantic Canada and the sixth in Canada to acquire advanced technology for treating patients suffering from ongoing pain due to fibroids, offering patients the option to preserve their uterus as an alternative to undergoing a hysterectomy. Several patients have already benefited from the purchase of this new technology —Acessa® Laparoscopic Radiofrequency Ablation (of fibroids) —, led by Dr. Stéphane Foulem, a gynecologist at TMH, and purchased by the Friends of The Moncton Hospital Foundation at a cost of $150,000. “This is game-changing technology. I can now offer my patients new interventions meaning less invasive, less recovery time, less downtime – allowing them to get back to living their best life,” said Dr. Foulem. “This is just another example of The Moncton Hospital being ahead of the curve – thanks to the Friends Foundation and its donors – helping patients not only in New Brunswick but Atlantic Canada as a whole.” “Having this modern technology puts Moncton on the map for a best-in-class fibroid treatment centre for women,” said Greg King, President and CEO of the Friends of The Moncton Hospital Foundation. “Our donors continue to make an impact on patient care. Support from the community is needed now more than ever to improve our health care.” “By acquiring this new technology, Horizon takes a significant step towards fulfilling its commitment to improving access to surgical services and enhancing the overall patient experience, particularly for those seeking fibroid treatment,” said Greg Doiron, Horizon’s Vice President of Clinical Operations. “I want to thank Dr. Foulem for his vision and acknowledge the support he received from his colleagues in Obstetrics and Gynecology. I truly appreciate the collaborative effort involved and commend your dedication to prioritizing patient care.” Fibroids are growths composed of smooth muscle cells and fibrous connective tissue within the uterus, affecting approximately 70 per cent of women in various forms. This innovative treatment, which effectively softens and shrinks fibroid tissues over time, offers a unique and less invasive approach compared to previous treatment methods. Carolle de Ste-Croix, who suffered with debilitating fibroids for years, is ecstatic that this technology is now available for women in Atlantic Canada. “Women who have this condition have a similar story. How can we change the ending? This equipment is the answer to changing that ending for women in our area,” said Ms. de Ste-Croix. Individuals across Atlantic Canada grappling with persistent fibroid-related pain are encouraged to consult their primary care providers for assessment and potential access to this treatment at Horizon’s The Moncton Hospital. – 30 – For more information contact: Kris McDavidMedia Relations1-877-499-1899media@horizonnb.cahorizonnb.ca/news Julie Thébeau, CFRE Director, Communications and Donor Experience Friends of The Moncton Hospital Foundation 506-381-9021 Julie.Thebeau@HorizonNB.ca Friendsfoundation.ca